Biolegend, 648888, Ultra-LEAF™ Purified anti-human CD55 Antibody, 100μg

CD55 is a 60-70 kD glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein also known as decay-accelerating factor (DAF). CD55 is expressed on hematopoietic cells, including erythrocytes, and many non-hematopoietic cells. CD55 accelerates the dissociation of the components of the C3-convertases (namely C2a from C4b in the C4bC2a complex, a C3-convertase of the classical pathway, and factor Bb from the C3bBb complex, a C3-convertase of the alternative pathway) to protect cells from inappropriate damage caused by autologous complement. CD55 has been reported to reduce the efficiency of NK cell lysis and induce signal transduction in T cells. CD55 has also been shown to interact with CD97 and bind to Coxsackie and Echovirus.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Human CD55 recombinant protein
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/μg of the protein (< 0.001 ng/μg of the protein) as determined by the LAL test
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Block - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by blocking the binding of 2 μg/mL immobilized human CD55 (Cat. No. TBD) to its receptor human CD97 (Cat. No. TBD) at 200 ng /mL. ND50 range: 0.2 – 1.2 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_3720630 (BioLegend Cat. No. 648888) AB_3720630 (BioLegend Cat. No. 648889)
Structure: GPI-anchored regulator of complement activation (RCA), type I membrane glycoprotein
Distribution: Hematopoietic cells including erythrocytes and many non-hematopoietic cells
Function: Protects against inappropriate complement activation and cell damage, induces signal transduction, reduces the efficiency of NK cell lysis
Ligand/Receptor: C3b, C4b, CD97, Coxsackie viruses
Antigen References: 1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. 2. Hamann J, et al. 1996. J. Exp. Med. 184:1185. 3. Fujita T, et al. 1987. J. Exp. Med. 166:1221.
Gene ID: NA
UniProt: View information about CD55 on UniProt.org
Clone: W24215H
Regulatory Status: RUO
Other Names: DAF (Decay Accelerating Factor)
Isotype: Rat IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.